Summer 2026
Posted on 10/30/2025
Manages public funds through investment portfolio
No salary listed
Madison, WI, USA
In Person
| , , , |
SWIB manages and invests Wisconsin’s public employee retirement funds and other state assets for residents. It pursues long-term investments across stocks, bonds, real assets, and alternatives using internal research, risk controls, and external managers to build diversified portfolios and meet actuarial targets while controlling costs. As a state agency, it operates with fiduciary responsibility to public funds, emphasizing prudent stewardship, transparency, and long-horizon investing at scale. Its goal is to maximize long-term returns for Wisconsin’s public retirement systems while keeping risk and costs in check to ensure stable funding for beneficiaries.
Company Size
N/A
Company Stage
N/A
Total Funding
N/A
Headquarters
Madison, Wisconsin
Founded
1951
Help us improve and share your feedback! Did you find this helpful?
Comprehensive benefits package
Educational and training opportunities
Tuition reimbursement
Hybrid work environment
Relocation Assistance
Professional Development Budget
Hybrid Work Options
Elephas Biosciences raised $40M in a Series B-2 funding round to accelerate the commercialization of its Elephas Live™ Platform, a live tumor profiling technology for predicting immunotherapy responses. The funding, supported by existing investors like Northpond Ventures and ARCH Venture Partners, will aid in launching the platform as a laboratory developed test in 2026. CEO Maneesh Arora highlighted the strong investor confidence and the company's progress towards improving cancer treatment.
Company advancing novel live tumor imaging diagnostic platformMADISON, Wis., Jan. 23, 2024 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a private company, announced today that it has raised $55 million in Series C funding. Venture Investors Health Fund and State of Wisconsin Investment Board (SWIB) led the round. Continuing investments were made by Northpond Ventures, ARCH Ventures, Sands Capital, Moore Strategic Ventures, Tao Invest, and WARF Ventures. With this $55 million Series C funding, this brings the total raised by Elephas to $116.5 million.Elephas is developing an oncology imaging diagnostics platform to predict response to immunotherapy using the latest advances in metabolic imaging. The platform utilizes live patient biopsies with intact native tumor architecture and treats them with potential therapies to predict response to treatment
/PRNewswire/ -- HistoSonics, Inc. (www.histosonics.com), the developer of a non-invasive, novel sonic beam therapy, announced today that it has raised $85...